In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions.
As many Americans are out of work and losing their health insurance due to the coronavirus disease 2019 (COVID-19) pandemic, pharmacies are finding ways to adapt and step up to the challenge in order to ensure that patients receive their treatments, panelists said Wednesday during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.
Currently, there are over 20 million Americans out of work due to the pandemic, many of whom were covered by employer-provided health care plans and will now be eligible for Medicaid under the Affordable Care Act.
Many patients are suddenly unsure of how to continue their care, and Bruce Japsen, a senior health care writer for Forbes, suggested checking the government health care websites to find out what benefits they are eligible for.
“We don’t want a co-pay to get in the way. We don’t want a deductible to get in the way. And we certainly don’t want them to…not go to the doctor [or get] care because they don’t think [primary care providers are] open or they’re afraid to leave their house,” said Japsen.
Changes to the Pharmacy Structure
Japsen mentioned that pharmacies are expected to do well during the pandemic because they are classified as essential businesses and may remain open.
Some pharmacies “saw a huge uptick in people getting their prescriptions because some insurance companies allowed people to get prescriptions for several months rather than 1 or 2. So then, guess what happened in April? They had fewer people coming to the store, which was kind of hurting their business,” he said.
Pharmacies have had to change how they run their business entirely, from exclusively using drive-throughs to investing in telemedicine and medication deliveries.
Pharmacies have also become testing centers for COVID-19 and may be points of access for vaccines. Benjamin McNabb, PharmD, the owner of Love Oak Pharmacy in Eastland, Texas, wants pharmacies to keep those designations and hopes pharmacies will provide greater access to vaccines and tests.
“I would like to see pharmacies be given that opportunity to maintain that designation and possibly enter into other point-of-care testing like for [glycated hemoglobin] and cholesterol testing. There’s a lot of things that pharmacists can do,” he said.
McNabb expects that that some storefronts for pharmacies, including his own, will reopen in the next few weeks, meaning that procedural changes will be needed.
“We have to think about requiring patients to wear masks as they enter. We will most likely have to have an employee stationed at the front door instructing people. Can we help clean their hands with a spray bottle of alcohol, since some of the sanitizers are hard to find?” he said.
Pharmacies across the nation will also have to contend with establishing capacity levels for reopening, as restaurants and stores are doing.
How Pharmacies Have Risen to the Challenge
McNabb pointed out that certain pharmacies have received government approval to produce their own hand sanitizers for the public in light of shortages during the pandemic.
“Nearly half of all independent pharmacies are still compounding pharmacies, and they’re making quite a bit of hand sanitizer. Many of them are donating it to their communities, their patients, local businesses, and health care first responders,” he said.
Additionally, pharmacies, especially in rural areas, have made continued efforts to maintain local relationships, which is more critical than people realize, according to McNabb.
“In certain rural areas where phone and internet access might be limited, it’s sometimes patients, especially the highest-need patients, who are the costliest….Achieving the best outcome possible is very difficult to do, sometimes, through telephonic means,” said McNabb.
Some, including McNabb’s pharmacy, have expanded their delivery services and telemedicine to include pharmacy personnel in order to ensure continued treatment management for at-home patients. Drivers can give information on health care and can provide blood pressure screenings for individuals at home.
“I think there’s a void that we can fill to partner with telemedicine, to partner with local physicians, especially in chronic disease management,” said McNabb.
Pharmacies have also taken initiative to ensure treatment for patients with underlying conditions who are considered to be at higher risk of developing COVID-19—related complications by encouraging use of value-based patient models.
“I think an interesting thing to be thinking about is how are we managing underlying health conditions that might be exacerbated by COVID-19? So, partnering with pharmacists for these guide-based delivery models, I think, is invaluable,” said McNabb.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.